What is it about?
Cancer in individuals suffering with HIV and AIDS has become a common source of morbidity and mortality, especially in the underdeveloped world in which Kaposi’s sarcoma (KS) is the most frequent type of tumour of vascular endothelium seen in patients with AIDS. Affected individuals are uniformly co-infected with HIV and HHV-8 virus. Various traditional chemotherapeutic approaches may be effective in patients with disseminated KS. Advances in the treatment of AIDS related KS have been achieved, even though a gold standard therapy has not yet been defined that can deliver the drug non-invasively. Novel concepts of drug therapy are aimed at targeting the factors associated with the pathogenesis of disease. Various local therapies are aimed at eradicating small lesions, systemic chemotherapies and formulations are used to treat extensive visceral involvement. Increased understanding of the mechanisms underlying viral tumorigenesis will hopefully portray new therapeutic strategy.
Featured Image
Why is it important?
The present literature discusses novel drug delivery strategy that has been investigated for the management of AIDS related KS. It also highlights, lipid based ultradeformable delivery systems that offers attractive drug delivery systems that will deliver its payload without using invasive technique, which may serve as a model for treatment paradigms of the future.
Perspectives
Although, many advancements in therapy have provided broader insight into the management of AIDS related KS still there is an unquestionable demand for safer and non-invasive drug delivery that can specifically target tumorous cells and overcome all the limitations related to invasive techniques. Lipid based transdermal drug delivery could provide a novel strategy and is still at an early stage of development and there are many approaches in which currently used medium for drug delivery can be improved in case of AIDS associated KS. Possible means of improvement are appropriate selection of the approach, production of novel drug delivery strategy and modification of the carrier system. It is expected that many other cytotoxic drugs will benefitted from transdermal delivery within liquid state modified liposomes. There is a clear cut need for such a system that can deliver the drugs to diseased site and into the target cells non- invasively and these modified liposomal systems represents leading technology in this area. Finally, liquid state modified liposomes can be represented as a remarkable potential carrier and their clinical utility should soon to be demonstrated and explored.
Mr Vijay Sharma
Rajiv Academy for Pharmacy, Mathura (U. P.) INDIA
Read the Original
This page is a summary of: Therapy Stratifications and Novel Approach in Pursuit of Aids Related Kaposi’s Sarcoma Management- A paradigm for Non Invasiveness, Current Drug Delivery, December 2015, Bentham Science Publishers,
DOI: 10.2174/1567201812666150507155556.
You can read the full text:
Contributors
The following have contributed to this page
